Padillo-Ruiz J, Garcia C, Suarez G, Blanco G, Munoz-Bellvis L, Justo I
Int J Surg. 2025; 110(12):7798-7805.
PMID: 39806742
PMC: 11634100.
DOI: 10.1097/JS9.0000000000002153.
Navez J, Pezzullo M, Bouchart C, Arsenijevic T, Demetter P, Closset J
BJS Open. 2024; 8(6).
PMID: 39601263
PMC: 11599710.
DOI: 10.1093/bjsopen/zrae134.
Jiang J, Krishna S
Gland Surg. 2024; 13(9):1659-1661.
PMID: 39421055
PMC: 11480875.
DOI: 10.21037/gs-24-158.
Miyashita M, Yoshioka R, Fukumura Y, Takamatsu M, Oba A, Ono Y
Ann Gastroenterol Surg. 2024; 8(5):860-867.
PMID: 39229551
PMC: 11368497.
DOI: 10.1002/ags3.12795.
Usui M, Uchida K, Hayasaki A, Kishiwada M, Mizuno S, Watanabe M
PLoS One. 2024; 19(7):e0307876.
PMID: 39058712
PMC: 11280245.
DOI: 10.1371/journal.pone.0307876.
Comparison of Laparoscopic and Open Pancreaticoduodenectomy on Operative Time, Oncological Outcomes, Bleeding, Morbidity, and Mortality.
Manivasagam S, Chandra J N
Cureus. 2024; 16(2):e53387.
PMID: 38435141
PMC: 10908422.
DOI: 10.7759/cureus.53387.
Imaging of pancreatic ductal adenocarcinoma - An update for all stages of patient management.
Bilreiro C, Andrade L, Santiago I, Marques R, Matos C
Eur J Radiol Open. 2024; 12:100553.
PMID: 38357385
PMC: 10864763.
DOI: 10.1016/j.ejro.2024.100553.
Vein Wall Invasion Is a More Reliable Predictor of Oncological Outcomes than Vein-Related Margins after Pancreaticoduodenectomy for Early Stages of Pancreatic Ductal Adenocarcinoma.
Ahuja M, Pande R, Chugtai S, Brown R, Cain O, Bartlett D
Diagnostics (Basel). 2023; 13(22).
PMID: 37998601
PMC: 10670022.
DOI: 10.3390/diagnostics13223465.
ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer.
Turner K, Wilson G, Patel S, Ahmad S
Ann Surg Oncol. 2023; 31(3):1884-1897.
PMID: 37980709
DOI: 10.1245/s10434-023-14585-y.
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.
Pedrazzoli S
J Clin Med. 2023; 12(20).
PMID: 37892599
PMC: 10607532.
DOI: 10.3390/jcm12206461.
Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma.
Slodkowski M, Wronski M, Karkocha D, Kraj L, Smigielska K, Jachnis A
Cancers (Basel). 2023; 15(9).
PMID: 37174050
PMC: 10177138.
DOI: 10.3390/cancers15092584.
The impact of resection margin distance on survival and recurrence in pancreatic ductal adenocarcinoma in a retrospective cohort analysis.
Obonyo D, Uslar V, Munding J, Weyhe D, Tannapfel A
PLoS One. 2023; 18(2):e0281921.
PMID: 36800357
PMC: 9937496.
DOI: 10.1371/journal.pone.0281921.
Plasma Extracellular Vesicle Characteristics as Biomarkers of Resectability and Radicality of Surgical Resection in Pancreatic Cancer-A Prospective Cohort Study.
Badovinac D, Goricar K, Lavrin T, Zavrtanik H, Dolzan V, Lenassi M
Cancers (Basel). 2023; 15(3).
PMID: 36765562
PMC: 9913838.
DOI: 10.3390/cancers15030605.
Pancreatoduodenectomy En Bloc With Superior Mesenteric Artery Resection for Borderline Resectable Pancreatic Cancer - A Case Report and Literature Review.
Petrea S, Bacalbasa N, Balescu I, Diaconu C, Stiru O, Cauni V
Cancer Diagn Progn. 2023; 3(1):135-138.
PMID: 36632596
PMC: 9801448.
DOI: 10.21873/cdp.10191.
The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.
Liu H, Nassour I, Lebowitz S, DAlesio M, Hampton E, Desilva A
HPB (Oxford). 2023; 25(3):320-329.
PMID: 36610939
PMC: 11199074.
DOI: 10.1016/j.hpb.2022.12.002.
Machine-learning based investigation of prognostic indicators for oncological outcome of pancreatic ductal adenocarcinoma.
Chang J, Liu Y, Saey S, Chang K, Shrader H, Steckly K
Front Oncol. 2022; 12:895515.
PMID: 36568148
PMC: 9773248.
DOI: 10.3389/fonc.2022.895515.
International assessment and validation of the prognostic role of lymph node ratio in patients with resected pancreatic head ductal adenocarcinoma.
Joliat G, Labgaa I, Sulzer J, Vrochides D, Zerbi A, Nappo G
Hepatobiliary Surg Nutr. 2022; 11(6):822-833.
PMID: 36523941
PMC: 9745624.
DOI: 10.21037/hbsn-21-99.
Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad A, Hodges J, AlMasri S, Paniccia A, Lee K, Bahary N
JAMA Surg. 2022; 158(1):55-62.
PMID: 36416848
PMC: 9685551.
DOI: 10.1001/jamasurg.2022.5696.
Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?.
Fossaert V, Mimmo A, Rhaiem R, Rached L, Brasseur M, Brugel M
Front Oncol. 2022; 12:980659.
PMID: 36387257
PMC: 9640996.
DOI: 10.3389/fonc.2022.980659.
Intraoperative Positive Pancreatic Parenchymal Resection Margin: Is It a True Indication of Completion Total Pancreatectomy after Partial Pancreatectomy for Pancreatic Ductal Adenocarcinoma?.
Jung J, Yoon S, Lee O, Shin S, Heo J, Han I
Curr Oncol. 2022; 29(8):5295-5305.
PMID: 36005158
PMC: 9406454.
DOI: 10.3390/curroncol29080420.